NC
ANAB icon

nVerses Capital’s AnaptysBio ANAB Stock Holding History

nVerses Capital’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$240K Buy
+3,557
New +$216K 0.37% 118
2026
Q1 		– Sell
-4,438
Closed -$215K – 357
2025
Q4 		$215K Buy
+4,438
New +$173K 0.48% 123
2024
Q4 		– Sell
-1,600
Closed -$53.6K – 50
2024
Q3 		$53.6K Buy
1,600
+1,400
+700% +$47.8K 0.02% 616
2024
Q2 		$5.01K Buy
+200
New +$4.66K ﹤0.01% 953

Other funds holding ANAB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

nVerses Capital's ANAB Position: Q2 2026 in Review

nVerses Capital opened a new position in AnaptysBio (ANAB) in Q2 2026: 3,557 shares worth $240K. The stake represents 0.37% of the portfolio and ranks #118 among its holdings. This is a return to the name: nVerses Capital previously reported a position in ANAB as recently as Q4 2025.

nVerses Capital first reported a position in ANAB in Q2 2024 and has held it in 4 quarters since. 136 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • nVerses Capital held 3,557 shares of AnaptysBio worth $240K as of Q2 2026.
  • AnaptysBio was a new nVerses Capital position in Q2 2026.
  • AnaptysBio made up 0.37% of nVerses Capital's portfolio in Q2 2026, its #118 holding.
  • nVerses Capital first reported a position in AnaptysBio in Q2 2024 and has held it in 4 quarters since.
  • 136 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.